|
|
| Research article summary (published 21 Jun 2009): |
Identification of patients with poorer survival in primary myelofibrosis based on the burden of JAK2V617F mutated allele.
Full Abstract
A total of 186 patients with primary myelofibrosis (PMF) were genotyped for JAK2V617F at diagnosis aimed at analyzing the correlation of mutational status and mutated allele burden with outcome variables, including time to anemia, leukocytosis, leukopenia, thrombocytopenia, massive splenomegaly, leukemia, and with overall survival. A total of 127 JAK2V617F-mutated patients (68% of whole series) were divided in quartiles of V617F allele burden. After a median follow-up of 17.2 months, 23 patients died, 15 because of leukemia. A JAK2V617F mutated status did not impact on the rate of leukemia transformation or overall survival. Patients in the lower quartile had shorter time to anemia and leukopenia and did not progress to large splenomegaly. Furthermore, survival was significantly reduced in the lower quartile compared with upper quartiles and JAK2 wild-type patients. In multivariate analysis, factors associated with reduced survival were age, a blast count more than 1%, and a JAK2V617F burden within first quartile. Causes of death in the lower quartile were represented mainly by systemic infections. We conclude that a low JAK2V617F allele burden at diagnosis is preferentially associated with a myelodepletive rather than myeloproliferative phenotype and represents an independent factor associated with shortened survival in patients with PMF.
Author information
Author/s: Guglielmelli, Paola (P); Barosi, Giovanni (G); Specchia, Giorgina (G); Rambaldi, Alessandro (A); Lo Coco, Francesco (F); Antonioli, Elisabetta (E); Pieri, Lisa (L); Pancrazzi, Alessandro (A); Ponziani, Vanessa (V); Delaini, Federica (F); Longo, Giovanni (G); Ammatuna, Emanuele (E); Liso, Vincenzo (V); Bosi, Alberto (A); Barbui, Tiziano (T); Vannucchi, Alessandro M (AM);
Affiliation: Unità Funzionale di Ematologia, Dipartimento di Area Critica, Università di Firenze, and Istituto Toscano Tumori, Firenze, Italy.
Journal and publication information
Publication Type: Journal Article; Research Support, Non-U.S. Gov't
Journal: Blood (Blood), published in United States. (Language: eng)
Reference: 2009-Aug; vol 114 (issue 8) : pp 1477-83
Dates: Created 2009/08/21; Completed 2009/09/30;
PMID: 19549988, status: MEDLINE (last retrieved date: 9/30/2009)
Sourced from the National Library of Medicine. Abstract text and other information may be subject to copyright.
External Links for this article
(including full text providers, if available):
Click Electronic Full-text Provider Links to see options for finding the electronic full text links to this article. Note there may be a subscription or fee required for access to the full text. See our FAQ for information on finding FREE full text articles.
This article may also be located in paper journal collections available in many libraries. Use the Journal and Publication Information above to find the full article.
MeSH headings (categories)
This article was linked to the MeSH Headings (categories) shown below.
Note: Bold headings indicate primary MeSH headings or qualifiers.
Associated Chemicals: Phenylalanine (63-91-2) ; Valine (7004-03-7) ; JAK2 protein, human (EC 2.7.1.112) ; Janus Kinase 2 (EC 2.7.1.112)Related articles
These are the most related articles currently in our database:
- Low JAK2V617F allele burden in primary myelofibrosis, compared to either a higher allele burden or unmutated status, is associated with inferior overall and leukemia-free survival.
22 Jan 2008 - Cytogenetic studies at diagnosis in polycythemia vera: clinical and JAK2V617F allele burden correlates.
5 Dec 2007 - Identification of JAK2V617F in patients with polycythemia is highly correlated with conventional criteria for diagnosis of polycythemia vera.
30 Dec 2006 - JAK2 V617F due to a novel TG --> CT mutation at nucleotides 1848-1849: diagnostic implication.
6 Mar 2007 - A der(18)t(9;18)(p13;p11) and a der(9;18)(p10;q10) in polycythemia vera associated with a hyperproliferative phenotype in transformation to postpolycythemic myelofibrosis.
13 Jan 2007 - Recurrent chromosomal aberration at 12q15 in chronic idiopathic myelofibrosis with or without JAK2(V617F) mutation.
17 Apr 2007 - Monitoring of the JAK2-V617F mutation by highly sensitive quantitative real-time PCR after allogeneic stem cell transplantation in patients with myelofibrosis.
Oct 2006 - Prognostic relevance of cytogenetics determined by fluorescent in situ hybridization in patients having myelofibrosis with myeloid metaplasia.
13 Dec 2006 - JAK2 V617F mutational status predicts progression to large splenomegaly and leukemic transformation in primary myelofibrosis.
19 Aug 2007 - JAK2(V617F) and leukemic transformation in myelofibrosis with myeloid metaplasia.
21 Mar 2006
Related Article Map
Legend:
- FREE Full text Article.
- Abstract only.
- Title only. More help.
See a larger map of 100+ related articles.